Ronac Mamtani, MD, MSCE

Ronac Mamtani, MD, MSCE, is an Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania.

Articles by Ronac Mamtani, MD, MSCE

Bladder Cancer Experts Note Implications of Upfront Enfortumab Vedotin Dose Reduction in Advanced Urothelial Carcinoma: With Ramy Sedhom, MD; Ryan Chow, MD; and Ronac Mamtani, MD, MSCE

ByRonac Mamtani, MD, MSCE,Ramy Sedhom, MD,Ryan D. Chow, MD

February 5th 2026

Ramy Sedhom, MD, Ryan Chow, MD, and Ronac Mamtani, MD, MSCE, discuss dose reducing enfortumab vedotin to improve tolerability, without in patients with bladder cancer

Latest Updated Articles

Bladder Cancer Experts Note Implications of Upfront Enfortumab Vedotin Dose Reduction in Advanced Urothelial Carcinoma: With Ramy Sedhom, MD; Ryan Chow, MD; and Ronac Mamtani, MD, MSCE
February 5th 2026

Ronac Mamtani, MD, MSCE

Articles by Ronac Mamtani, MD, MSCE

Bladder Cancer Experts Note Implications of Upfront Enfortumab Vedotin Dose Reduction in Advanced Urothelial Carcinoma: With Ramy Sedhom, MD; Ryan Chow, MD; and Ronac Mamtani, MD, MSCE

Latest Updated Articles

Trending on OncLive

Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC

The OncFive: Top Oncology Articles for the Week of 6/28

Five Under 5: Top Oncology Videos for the Week of 6/28

FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies

Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera